2410 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TYK Medicines, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$55.50 |
| 52 Week High | HK$56.55 |
| 52 Week Low | HK$12.86 |
| Beta | 0 |
| 1 Month Change | 77.60% |
| 3 Month Change | 80.78% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 305.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2410 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 18.1% | -2.7% | 1.5% |
| 1Y | n/a | -9.2% | 20.6% |
Return vs Industry: Insufficient data to determine how 2410 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2410 performed against the Hong Kong Market.
Price Volatility
| 2410 volatility | |
|---|---|
| 2410 Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.0% |
Stable Share Price: 2410's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2410's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 144 | Yusheng Wu | www.tykmedicines.com |
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors.
TYK Medicines, Inc Fundamentals Summary
| 2410 fundamental statistics | |
|---|---|
| Market cap | HK$20.58b |
| Earnings (TTM) | -HK$455.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-45.2x
P/E RatioIs 2410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2410 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥427.94m |
| Earnings | -CN¥427.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -7.7% |
How did 2410 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 07:47 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TYK Medicines, Inc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|